St. Louis–based law firm Carey, Danis & Lowe announces the filing of a lawsuit on behalf of 18 plaintiffs against Pfizer (NYSE: PFE), maker of the antidepressant drug Zoloft.
Zoloft (generic name sertraline) belongs to a class of drugs known as selective serotonin reuptake inhibitors, or SSRIs. The U.S. Food and Drug Administration has approved Zoloft for the treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, acute post–traumatic stress disorder, premenstrual dysphoric disorder and social anxiety disorder.
The lawsuit, Shainyah Lancaster, et al. v. Pfizer, Inc., cause no. 1222-CC00766, was filed on Feb. 2 in St. Louis Circuit Court on behalf of 18 children born with defects after their mothers were prescribed Zoloft while pregnant. The suit was brought on behalf of the plaintiffs by the law firms of Carey, Danis & Lowe; Matthews & Associates; Freese & Goss; and Clark, Burnett, Love & Lee.
The suit notes that SSRIs have been found to cause severe birth defects in the children of women who were prescribed the drug while pregnant and alleges that Pfizer knew or should have known of SSRI studies revealing that children born to mothers who had taken SSRIs during pregnancy had a greater risk of congenital birth defects such as atrial septal defect, multiple holes in the heart and persistent pulmonary hypertension of the newborn. The plaintiffs also allege that Pfizer knew that physicians were prescribing Zoloft to women of childbearing age but failed to adequately warn the medical community and the public of the danger.The lawsuit asserts state law claims against Pfizer of negligence; negligence of pharmacovigilance, which requires Pfizer to monitor safety data for its drugs; strict liability; negligent design; failure to warn; and fraud. The suit seeks actual and punitive damages. “Since the 1990s, mounting evidence has shown that SSRIs, including Zoloft, are dangerous for pregnant mothers and their developing babies,” explains Jeffrey J. Lowe of Carey, Danis & Lowe. “Unfortunately, Pfizer hid that information.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV